CUPERTINO, Calif., June 11 /PRNewswire-FirstCall/ —
DURECT Corporation (Nasdaq: DRRX) announced today that it proposes to offer a
new issue of $50 million of Convertible Notes due 2008 through a Rule 144A
offering to qualified institutional buyers. These notes will be convertible
into DURECT common stock at a price to be determined. The Company has granted
the initial purchaser of the Notes an option to purchase an additional $10
million principal amount of the Notes.
The Notes and common stock issuable upon conversion of the Notes have not
been registered under the Securities Act of 1933, as amended, or applicable
state securities laws, and unless so registered, may not be offered or sold in
the United States, except pursuant to an applicable exemption from the
registration requirements of the Securities Act of 1933, as amended, and
applicable state securities laws.
This press release shall not constitute an offer to sell or the
solicitation of an offer to sell or the solicitation of an offer to buy the
Notes. This press release is being issued pursuant to and in accordance with
Rule 135c under the Securities Act of 1933, as amended.
The statements in this press release regarding DURECT’s financing
activities are forward-looking statements involving risks and uncertainties
that can cause actual results to differ materially from those in such forward-
looking statements. Potential risks and uncertainties include, but are not
limited to, DURECT’s ability to raise additional capital. Further information
regarding these and other risks is included in DURECT’s Annual Report on Form
10-K for the fiscal year ended December 31, 2002 filed with the SEC on March
14, 2003, DURECT’s Quarterly Report on Form 10Q and other periodic reports
filed with the SEC under the heading “Factors that may affect future results.”
SOURCE DURECT Corporation
CONTACT: Schond L. Greenway, Senior Director, Investor Relations and
Strategic Planning of DURECT Corporation, +1-408-777-1417, or
schond.greenway@durect.com/
/Web site: http://www.www.durect.com /
(DRRX)